Data protection Impressum

Biotech

At the crossroads of tradition and innovation, the University of Fribourg’s Section of Medicine offers a distinct vision for the future of healthcare. As part of Switzerland’s only fully bilingual university, the Section of Medicine is advancing both education and translational research in a collaborative, human-focused environment.

Why Switzerland

The University of Fribourg’s human-centered approach to medicine

Top Stories Western Switzerland

Top Stories from Western Switzerland (May 2025)

28 May 2025

In the heart of Fribourg, the Adolphe Merkle Institute (AMI) has grown into a globally recognized center of excellence in materials science. Founded in 2008 through the visionary endowment of Swiss entrepreneur Dr. Adolphe Merkle, the institute was built on a simple yet powerful belief: fundamental science can bridge the gap to real-world impact.

Adolphe Merkle Institute: Where science meets application in the heart of Fribourg

Western Switzerland is rapidly becoming a hotspot for biomanufacturing and life sciences companies, thanks to its strong infrastructure, skilled talent, and business-friendly policies. Yassin Nahi, GGBa (Greater Geneva Bern area) Life Science Director, shares how the region's research hubs, academic institutions, and regulatory support make it an ideal location for companies in this sector.

Why Western Switzerland for Biomanufacturing and Life Sciences Companies: an interview with expert Yassin Nahi

Hedera Dx has secured EUR 15 million to expand hospital-based cancer diagnostics, making precision oncology more accessible to patients worldwide.

Hedera Dx raises EUR 15 million to expand access to precision cancer care

27 May 2025

Lausanne-based biotech ReproNovo has secured USD 65 million to advance Phase 2 trials for novel therapies in male infertility and women’s reproductive health.

ReproNovo raises USD 65 million to advance trials in reproductive health

21 May 2025

Inaugurated in May 2025, the PULSE Innovation Center in Cheseaux-sur-Lausanne is emerging as a flagship site for life sciences and high-tech companies in Western Switzerland, offering modular infrastructure, shared services, and a unique environment for collaboration and growth.

PULSE, a new era for innovation in Western Switzerland

21 May 2025

HAYA Therapeutics, a precision medicine company based at Biopôle in Lausanne, has closed a USD 65 million Series A funding round to accelerate the clinical development of its RNA-guided therapies and expand its regulatory genome platform.

HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease

12 May 2025

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: building resilience through global alliances

6 May 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2025)

23 April 2025

1 2 3 4 5 … 21